Analyst Ratings For Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)
Today, Morgan Stanley lowered its price target on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) to $38.00 per share.
There are 5 buy ratings on the stock.
The current consensus rating on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) is Buy (Score: 3.00) with a consensus target price of $40.80 per share, a potential 14.74% upside.
Some recent analyst ratings include
- 9/12/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 5/30/2017-William Blair initiated coverage with a Outperform rating.
- 5/30/2017-Barclays PLC initiated coverage with a Overweight rating.
Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)
Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at with shares trading hands.